ERC Starting Grant · 2021
Detecting epigenetic biomarkers in the blood for non-invasive precision oncology
The detection of circulating tumor DNA allows to non-invasively retrieve tumor molecular profiles and follow disease evolution. These approaches promise optimal and individualized management of patients with cancer. However, despite remarkable progress, several technological obstacles still limit liquid biopsy widespread application. Indeed, detecting small fractions of tumor DNA released when the tumor burden is reduced remains a challenge. Samples collected at early stages or during treatment may contain less than one mutant copy per milliliter of plasma, which is below the detection limit of current technologies. Moreover, detectable recurrent mutations do not cover all patients. It is…
From the public funding record at EU CORDIS. Describes the funded project, not the reviews below.
← All labs at National Institute of Health and Medical Research (INSERM)